U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Mental Health (UK). Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. Leicester (UK): British Psychological Society (UK); 2005. (NICE Clinical Guidelines, No. 28.)

Cover
  • In June 2019 NICE updated the recommendations on psychological therapy in this guideline and in March 2015 NICE updated the recommendations on combination therapy. Most of the 2005 recommendations have been retained in NICE guideline NG134 depression in children and young people. The 2005 full guideline includes the evidence supporting those 2005 recommendations. Areas redacted in the PDF of this 2005 full guideline indicate areas that have been replaced by the 2015 or 2019 updates

In June 2019 NICE updated the recommendations on psychological therapy in this guideline and in March 2015 NICE updated the recommendations on combination therapy. Most of the 2005 recommendations have been retained in NICE guideline NG134 depression in children and young people. The 2005 full guideline includes the evidence supporting those 2005 recommendations. Areas redacted in the PDF of this 2005 full guideline indicate areas that have been replaced by the 2015 or 2019 updates

Cover of Depression in Children and Young People

Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care.

Show details

Appendix VAntidepressant drug treatment – forest plots

Fluoxetine vs. placebo - Non-remission

Fluoxetine vs. placebo - Non-response to treatment

Fluxetine vs. placebo - Depressive symptoms

Fluxetine vs. placebo - Functional status

Fluxetine vs. placebo - Global improvement

Fluxetine vs. placebo - Severity of illness

Fluxetine vs. placebo - Adverse events

Fluoxetine vs. placebo - Discontinuation from treatment

Fluoxetine vs. placebo - Suicidality (FDA re-analysis)

Paroxetine vs. placebo - Non-remission

Paroxetine vs. placebo - Depressive symptoms

Paroxetine vs. placebo - Non-response to treatment

Paroxetine vs. placebo - Functional status

Paroxetine vs. placebo - Global improvement

Paroxetine vs. placebo - Adverse events

Paroxetine vs. placebo - Individual adverse events (that occurred > 5% and at greater rate than placebo

Paroxetine vs. placebo - Discontinuation from treatment

Paroxetine vs. placebo - Individual adverse events

Paroxetine vs. placebo - Suicidality (FDA re-analysis)

Sertaline vs. placebo - Non-remission

Sertaline vs. placebo - Non-response to treatment

Sertaline vs. placebo - Depressive symptoms

Sertaline vs. placebo - Functional status

Sertaline vs. placebo - Suicidality (FDA re-analysis)

Sertaline vs. placebo - Global improvement

Sertaline vs. placebo - Severity of illness

Sertaline vs. placebo - Adverse events

Sertaline vs. placebo - Discontinuation from treatment

Citalopram vs. placebo

Citalopram vs. placebo - Non-remission

Citalopram vs. placebo - Suicidality (FDA re-analysis)

Venlafaxine vs. placebo - Depressive symptoms

Venlafaxine vs. placebo - CDRS-R

Venlafaxine vs. placebo - Discontinuation due to adverse events

Venlafaxine vs. placebo - Individual adverse events (events that occured > 5% and at greater rate than place

Venlafaxine vs. placebo - Suicidality (FDA re-analysis)

Mirtazapine vs. placebo - Depressive symptoms

Mirtazapine vs. placebo - Discontinuation due to adverse events

Mirtazapine vs. placebo - Individual adverse events (events that occurred > 5% and at a greater rate than place

Mirtazapine vs. placebo - Suicidality (FDA re-analysis)

Nefazodone vs. placebo - Suicidality (FDA re-analysis)

SSRIs vs. placebo - Serious adverse events

SSRIs vs. placebo - "Outcome 3: definitive suicidal behaviour/ideation" (FDA re-analysis)

SSRIs vs. placebo - Discontinuation due to adverse events

SSRIs vs. placebo - Discontinuation from treatment

SSRIs vs. placebo - Treatment-emergent hostility or agitation (FDA re-analysis)

Fluoxetine + CBT vs. placebo

Fluoxetine + CBT vs. fluoxetine alone

Fluoxetine + CBT vs. CBT alone

Fluoxetine alone vs. CBT alone

Copyright © 2005, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

Bookshelf ID: NBK56423
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this page (184K)
  • PDF version of this title (2.9M)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...